Tomas Kiselak - Jun 26, 2024 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Role
Director
Signature
/s/ Jennifer Tousignant, Attorney-in-Fact for Tomas Kiselak
Stock symbol
VRDN
Transactions as of
Jun 26, 2024
Transactions value $
$0
Form type
4
Date filed
6/28/2024, 04:05 PM
Previous filing
Jun 16, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRDN Stock Option (Right to Buy) Award $0 +21K $0.00 21K Jun 26, 2024 Common Stock 21K $12.31 See Footnote F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests in full upon the earlier to occur of (i) June 26, 2025 or (ii) the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board.
F2 Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.

Remarks:

Exhibit 24 - Power of Attorney